NEW YORK (GenomeWeb) – Thermo Fisher Scientific said on Monday that it has received clearance from the US Food and Drug Administration for the de novo submission of its Thermo Scientific QMS Plazomicin Immunoassay.

The quantitative immunoassay measures the concentration of a novel antibiotic, Zemdri (plazomicin), using the automated clinical chemistry analyzer Beckman Coulter AU 680.

Plazomicin is a next-generation aminoglycoside antibiotic that is used to treat patients with complicated urinary tract infections.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.